RESUMO
INTRODUCTION: Results from the CASPIAN trial (Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer) trial demonstrated the clinical benefit of durvalumab plus etoposide-platinum (EP) chemotherapy as first-line treatment for patients with extensive stage small-cell lung cancer (ES-SCLC). However, considering the high price of durvalumab, it is unclear whether addition of durvalumab to EP chemotherapy has economic value compared with EP alone. In this study, we aimed to evaluate the cost-effectiveness of durvalumab plus EP chemotherapy as a first-line treatment for patients with ES-SCLC. METHODS: A Markov model comprising three health states (stable, progressive, and dead) was developed to simulate the process of small-cell lung cancer. Utility and costs were obtained from published resources. Health outcomes were derived from the CASPIAN trial. Costs were calculated based on the standard medical fees in Zhejiang Province from Chinese patients' perspective. Utility values were obtained from published data. One-way and probabilistic sensitivity analyses were applied to verify model robustness. RESULTS: The addition of durvalumab to EP chemotherapy costs more than $32,220, with a gain of 0.14 quality-adjusted life years (QALYs) compared with EP alone. The incremental cost-effective ratio was $230,142.9 per QALY, which exceeds the willingness to pay threshold of $28,527 per QALY. In the sensitivity analysis, the utility values for the progressive state, costs of durvalumab and EP chemotherapy, and costs for the progressive state were considered to be the three most sensitive factors in the model. CONCLUSION: The addition of durvalumab to EP chemotherapy is not a cost-effective strategy in the first-line therapy of ES-SCLC from the Chinese payers' perspective.
Assuntos
Análise Custo-Benefício/economia , Platina/uso terapêutico , Carcinoma de Pequenas Células do Pulmão/tratamento farmacológico , Carcinoma de Pequenas Células do Pulmão/economia , Anticorpos Monoclonais/economia , Anticorpos Monoclonais/uso terapêutico , Anticorpos Monoclonais Humanizados/economia , Anticorpos Monoclonais Humanizados/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/economia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , China/epidemiologia , Etoposídeo/economia , Etoposídeo/uso terapêutico , Feminino , Humanos , Masculino , Cadeias de Markov , Estadiamento de Neoplasias , Platina/economia , Intervalo Livre de Progressão , Anos de Vida Ajustados por Qualidade de Vida , Ensaios Clínicos Controlados Aleatórios como Assunto , Carcinoma de Pequenas Células do Pulmão/patologiaRESUMO
BACKGROUND: The phase III KEYNOTE-604 study confirmed the benefit of pembrolizumab combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). Taken into account the clinical benefits of pembrolizumab and its high cost, this study aimed to assess the cost-effectiveness of adding pembrolizumab to standard first-line etoposide-platinum (EP) for patients with ES-SCLC from the US payer perspective. METHODS: A Markov model was developed to compare the cost and quality-adjusted life-year (QALY) of pembrolizumab plus EP and placebo plus EP over a 10-year time horizon. Clinical efficacy and safety data were pooled from the KEYNOTE-604 trial. Utilities were obtained from published resources. Costs were mainly collected from Medicare in 2020. Sensitivity analyses were performed to examine the robustness of our model. RESULTS: Adding pembrolizumab to standard first-line EP resulted in the better effectiveness than EP chemotherapy alone for ES-SCLC by 0.22 QALYs. Pembrolizumab plus EP was dominated economically by placebo plus EP, leading to an incremental cost-effectiveness ratio (ICER) of $334,373/ QALY. Deterministic sensitivity analyses indicated that the uncertainty in model parameters exerted no substantial effect on our results. Probability sensitivity analysis indicated that probabilities for pembrolizumab plus EP being cost-effective within a wide range of willingness to pay were modest. CONCLUSION: From the US payer perspective, the first-line treatment for ES-SCLC with pembrolizumab plus EP was not cost-effective compared with placebo plus EP. Although pembrolizumab combination chemotherapy was beneficial to the survival of ES-SCLC, price reduction may be the necessary to improve its cost-effectiveness.
Assuntos
Anticorpos Monoclonais Humanizados/uso terapêutico , Antineoplásicos Imunológicos/uso terapêutico , Antineoplásicos Fitogênicos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Análise Custo-Benefício/métodos , Etoposídeo/uso terapêutico , Imunoterapia/métodos , Neoplasias Pulmonares/tratamento farmacológico , Platina/uso terapêutico , Carcinoma de Pequenas Células do Pulmão/tratamento farmacológico , Anticorpos Monoclonais Humanizados/economia , Antineoplásicos Imunológicos/economia , Antineoplásicos Fitogênicos/economia , Protocolos de Quimioterapia Combinada Antineoplásica/economia , Método Duplo-Cego , Etoposídeo/economia , Seguimentos , Humanos , Neoplasias Pulmonares/epidemiologia , Neoplasias Pulmonares/patologia , Cadeias de Markov , Medicare , Estadiamento de Neoplasias , Intervalo Livre de Progressão , Anos de Vida Ajustados por Qualidade de Vida , Carcinoma de Pequenas Células do Pulmão/epidemiologia , Carcinoma de Pequenas Células do Pulmão/patologia , Estados Unidos/epidemiologiaRESUMO
BACKGROUND: The optimal chemotherapy regimen for treating HIV associated NHL in low resource settings is unknown. We conducted a retrospective study to describe survival rates, treatment response rates and adverse events in patients with HIV associated NHL treated with CHOP and dose adjusted-EPOCH regimens at the Uganda Cancer Institute. METHODS: A retrospective study of patients diagnosed with HIV and lymphoma and treated at the Uganda Cancer Institute from 2016 to 2018 was done. RESULTS: One hundred eight patients treated with CHOP and 12 patients treated with DA-EPOCH were analysed. Patients completing 6 or more cycles of chemotherapy were 51 (47%) in the CHOP group and 8 (67%) in the DA-EPOCH group. One year overall survival (OS) rate in patients treated with CHOP was 54.5% (95% CI, 42.8-64.8) and 80.2% (95% CI, 40.3-94.8) in those treated with DA-EPOCH. Factors associated with favourable survival were BMI 18.5-24.9 kg/m2, (p = 0.03) and completion of 6 or more cycles of chemotherapy, (p < 0.001). The overall response rate was 40% in the CHOP group and 59% in the DA-EPOCH group. Severe adverse events occurred in 19 (18%) patients in the CHOP group and 3 (25%) in the DA-EPOCH group; these were neutropenia (CHOP = 13, 12%; DA-EPOCH = 2, 17%), anaemia (CHOP = 12, 12%; DA-EPOCH = 1, 8%), thrombocytopenia (CHOP = 7, 6%; DA-EPOCH = 0), sepsis (CHOP = 1), treatment related death (DA-EPOCH = 1) and hepatic encephalopathy (CHOP = 1). CONCLUSION: Treatment of HIV associated NHL with curative intent using CHOP and infusional DA-EPOCH is feasible in low resource settings and associated with > 50% 1 year survival.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Infecções por HIV/complicações , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Adulto , Anemia/induzido quimicamente , Anemia/economia , Anemia/epidemiologia , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/economia , Ciclofosfamida/administração & dosagem , Ciclofosfamida/efeitos adversos , Ciclofosfamida/economia , Doxorrubicina/administração & dosagem , Doxorrubicina/efeitos adversos , Doxorrubicina/economia , Esquema de Medicação , Etoposídeo/administração & dosagem , Etoposídeo/efeitos adversos , Etoposídeo/economia , Feminino , Infecções por HIV/imunologia , Encefalopatia Hepática/induzido quimicamente , Encefalopatia Hepática/economia , Encefalopatia Hepática/epidemiologia , Humanos , Infusões Intravenosas/economia , Infusões Intravenosas/métodos , Linfoma Difuso de Grandes Células B/economia , Linfoma Difuso de Grandes Células B/imunologia , Linfoma Difuso de Grandes Células B/mortalidade , Masculino , Pessoa de Meia-Idade , Neutropenia/induzido quimicamente , Neutropenia/economia , Neutropenia/epidemiologia , Prednisona/administração & dosagem , Prednisona/efeitos adversos , Prednisona/economia , Estudos Retrospectivos , Sepse/induzido quimicamente , Sepse/economia , Sepse/epidemiologia , Taxa de Sobrevida , Trombocitopenia/induzido quimicamente , Trombocitopenia/economia , Trombocitopenia/epidemiologia , Fatores de Tempo , Resultado do Tratamento , Uganda/epidemiologia , Vincristina/administração & dosagem , Vincristina/efeitos adversos , Vincristina/economiaRESUMO
BACKGROUND: Several strategies are available for the initial treatment of advanced-stage Hodgkin lymphoma, but the optimal strategy in terms of cost-effectiveness is unclear. The aim of this study was to compare the quality-adjusted effectiveness and costs of five modern treatment options for transplantation-eligible patients with newly diagnosed advanced-stage Hodgkin lymphoma. METHODS: A Markov decision-analytic model was developed using a 20-year time horizon. Five of the most common treatment approaches were selected based on clinical experience and expert opinion: (1) six cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD), including data from the HD2000 trial, Viviani and colleagues, and EORTC trial; (2) six cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP; from the HD15 trial or PET-adapted as in the HD18 trial, two initial cycles of BEACOPP followed by four additional cycles for patients with a positive PET and either two or four additional cycles of BEACOPP for patients with a negative PET); (3) PET-adapted escalation (as in the RATHL trial, two cycles of standard ABVD chemotherapy followed by an additional four cycles of ABVD or AVD in PET-negative patients and four cycles of BEACOPP in PET-positive patients); (4) six cycles of brentuximab vedotin, doxorubicin, vinblastine, dacarbazine (A-AVD) or ABVD as in the Echelon-1 trial; and (5) PET-adapted de-escalation (as in the AHL2011 trial, two cycles of BEACOPP followed by PET2 scan; PET-positive patients received two additional BEACOPP cycles and PET-negative patients received two cycles of ABVD; at PET4, PET-negative patients completed two further cycles of either ABVD or BEACOPP depending on what they received after PET2, and PET-positive patients received salvage therapy). Note that all uses of BEACOPP in these strategies were BEACOPPescalated. The randomised groups of interest from these studies comprised 4255 patients enrolled between April, 2000, and January, 2016. Baseline probability estimates and utilities were derived from the included trials in addition to a systematic review of published studies. A Canadian public health payer's perspective was considered (CAN$1=US$0·74) and adjusted for inflation for 2018. All costs and benefits were discounted by 1·5% per year because life-years now are more valuable than future potential life-years. FINDINGS: Probabilistic analyses (10â000 simulations) showed that, for a willingness-to-pay threshold of CAN$50â000, a PET-adapted de-escalation strategy based on AHL2011 was more cost-effective 87% of the time. This strategy had the highest number of life-years (14·6 years [95% CI 13·7-15·1]) and quality-adjusted life years (13·2 years [95% CI 10·2-14·4]), and the lowest direct costs ($53â129 [95% CI 31â914-94â446]) compared with the other treatment regimens. Sensitivity analyses showed that the model was robust to key variables, including probability of treatment-related mortality, relapse, frequency of secondary malignancy, death from secondary malignancy, and probability of infertility after BEACOPP. INTERPRETATION: Our results suggest that, when considering cost, effectiveness, and short and long-term toxicities, the preferred treatment strategy for patients with newly diagnosed advanced-stage Hodgkin lymphoma is the PET-adapted de-escalation regimen starting with BEACOPP and de-escalating to ABVD as appropriate. Although our findings do not provide an absolute best treatment approach for clinicians to follow for all patients, they can contribute to shared decision making between patients and treating physicians. FUNDING: None.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica , Doença de Hodgkin , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/economia , Bleomicina/administração & dosagem , Bleomicina/economia , Canadá , Análise Custo-Benefício , Ciclofosfamida/administração & dosagem , Ciclofosfamida/economia , Dacarbazina/administração & dosagem , Dacarbazina/economia , Doxorrubicina/administração & dosagem , Doxorrubicina/economia , Etoposídeo/administração & dosagem , Etoposídeo/economia , Feminino , Seguimentos , Doença de Hodgkin/tratamento farmacológico , Doença de Hodgkin/economia , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Tomografia por Emissão de Pósitrons , Prednisona/administração & dosagem , Prednisona/economia , Procarbazina/administração & dosagem , Procarbazina/economia , Vimblastina/administração & dosagem , Vimblastina/economia , Vincristina/administração & dosagem , Vincristina/economiaRESUMO
PURPOSE: Drug wastage is a major concern in oncology where costs of antineoplastic drugs are exorbitant, and the disposal of toxic drugs increases the chances of occupational hazards to healthcare and sanitary workers and environmental pollution at the site of disposal. The principal objective of this study was to ascertain the extent of drug wastage and calculate its financial costs. MATERIALS AND METHODS: This was a prospective pilot study conducted to ascertain the quantity of drug wastage in a tertiary care hospital. This pilot study was conducted in day care and inpatient facilities in February 2016. The prescription of cytotoxic drugs, recommended dose, the quantity used, and remainder (waste) left were recorded from the nurses and pharmacy files of the hospital. Cost evaluation of the actual use and the waste was undertaken and an audit was conducted to understand in which anticancer drug the maximum wastage was generated. RESULTS: The results of this study indicated that 6.1% of the total amount of reconstituted drugs was wasted. The highest drug wastage was observed in trastuzumab (29.55%), followed by etoposide (20.4%), dacarbazine (17.14%), daunorubicin (16.67%), and carboplatin (11.29%). Cost analysis showed that the total cost of the drug issued during the study period was Rs. 1,294,975 and the cost of drug wastage amounted to Rs. 143,820 (11.1%). CONCLUSION: To the best of authors' knowledge, this is the first study from India and the results indicate that the financial impact of anticancer drug wastage was substantial. Attempts should be directed at minimizing the wastage and cost savings without risking patients' treatment regimen and administering effective dose schedule.
Assuntos
Antineoplásicos/economia , Caquexia/tratamento farmacológico , Análise Custo-Benefício , Centros de Atenção Terciária/economia , Antineoplásicos/uso terapêutico , Caquexia/economia , Caquexia/patologia , Carboplatina/economia , Carboplatina/uso terapêutico , Dacarbazina/economia , Dacarbazina/uso terapêutico , Daunorrubicina/economia , Daunorrubicina/uso terapêutico , Etoposídeo/economia , Etoposídeo/uso terapêutico , Feminino , Auditoria Financeira , Humanos , Índia/epidemiologia , Masculino , Projetos Piloto , Estudos Prospectivos , Trastuzumab/economia , Trastuzumab/uso terapêuticoRESUMO
Burkitt lymphoma is an aggressive B cell malignancy accounting for 1-2% of all adult lymphomas. Treatment with dose-intensive, multi-agent chemotherapy is effective but associated with considerable toxicity. In this observational study, we compared real-world efficacy, toxicity, and costs of four frequently employed treatment strategies for Burkitt lymphoma: the Lymphome Malins B (LMB), the Berlin-Frankfurt-Münster (BFM), the HOVON, and the CODOX-M/IVAC regimens. We collected data from 147 adult patients treated in eight referral centers. Following central pathology assessment, 105 of these cases were accepted as Burkitt lymphoma, resulting in the following treatment groups: LMB 36 patients, BFM 19 patients, HOVON 29 patients, and CODOX-M/IVAC 21 patients (median age 39 years, range 14-74; mean duration of follow-up 47 months). There was no significant difference between age, sex ratio, disease stage, or percentage HIV-positive patients between the treatment groups. Five-year progression-free survival (69%, p = 0.966) and 5-year overall survival (69%, p = 0.981) were comparable for all treatment groups. Treatment-related toxicity was also comparable with only hepatotoxicity seen more frequently in the CODOX/M-IVAC group (p = 0.004). Costs were determined by the number of rituximab gifts and the number of inpatients days. Overall, CODOX-M/IVAC had the most beneficial profile with regards to costs, treatment duration, and percentage of patients completing planned treatment. We conclude that the four treatment protocols for Burkitt lymphoma yield nearly identical results with regards to efficacy and safety but differ in treatment duration and costs. These differences may help guide future choice of treatment.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Linfoma de Burkitt/tratamento farmacológico , Análise Custo-Benefício , Infecções por HIV/tratamento farmacológico , Adolescente , Adulto , Idoso , Linfoma de Burkitt/complicações , Linfoma de Burkitt/economia , Linfoma de Burkitt/mortalidade , Carmustina/economia , Carmustina/uso terapêutico , Ciclofosfamida/economia , Ciclofosfamida/uso terapêutico , Citarabina/economia , Citarabina/uso terapêutico , Etoposídeo/economia , Etoposídeo/uso terapêutico , Feminino , Infecções por HIV/complicações , Infecções por HIV/economia , Infecções por HIV/mortalidade , Humanos , Ifosfamida/economia , Ifosfamida/uso terapêutico , Masculino , Melfalan/economia , Melfalan/uso terapêutico , Metotrexato/economia , Metotrexato/uso terapêutico , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Estudos Retrospectivos , Rituximab/economia , Rituximab/uso terapêutico , Análise de SobrevidaRESUMO
Reducing delays related to inpatient chemotherapy may reduce healthcare costs. Using a national database, we identified patients with lymphoma/leukemia with ≥1 etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone (EPOCH) chemotherapy claim and evaluated chemotherapy initiation delay (ID), >1 day from admission. Standard tests/procedures prior to initiation were evaluated. Among 4453 inpatient cycles, 19.7% had ID, odds ratio 2.28 (95% confidence interval: 1.83-2.85) with cycle 1 compared to cycle 2, and mean costs were higher in patients with ID than without ID (p < .0001). Prior to cycle 1, patients were more likely to undergo routine diagnostic procedures compared to subsequent cycles. Efforts to perform routine procedures prior to admission may reduce hospital length of stay and costs.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Tempo de Internação/economia , Leucemia/tratamento farmacológico , Linfoma/tratamento farmacológico , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/economia , Ciclofosfamida/economia , Ciclofosfamida/uso terapêutico , Doxorrubicina/economia , Doxorrubicina/uso terapêutico , Etoposídeo/economia , Etoposídeo/uso terapêutico , Feminino , Custos de Cuidados de Saúde , Humanos , Pacientes Internados , Leucemia/economia , Linfoma/economia , Masculino , Pessoa de Meia-Idade , Prednisona/economia , Prednisona/uso terapêutico , Resultado do Tratamento , Vincristina/economia , Vincristina/uso terapêuticoRESUMO
BACKGROUND: Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH)-containing regimens are frequently utilized in non-Hodgkin's lymphoma, however, the incidence of febrile neutropenia (FN) in patients receiving inpatient versus outpatient EPOCH has not been described. Additionally, no comparisons have been made regarding financial implications of EPOCH administration in either setting. This study's primary objective was to compare hospital admissions for FN in patients receiving inpatient or outpatient EPOCH. METHODS: A single-center, institutional review board-approved review was conducted for adults receiving EPOCH beginning January 2010. Clinical and financial data were collected through chart review and the institution's financial department. Descriptive statistics were utilized for analysis. RESULTS: A total of 25 patients received 86 cycles of an EPOCH-containing regimen (61 [70.9%] inpatient). Five (8.2%) inpatient cycles resulted in an admission for FN compared to 4 (16%) outpatient cycles. Prophylactic antifungal and antiviral agents were prescribed more often after inpatient cycles (>80%) compared to outpatient cycles (<50%). Overall, 27 (31.4%) of 86 cycles did not receive granulocyte colony-stimulating factor support. Outpatient EPOCH administration was associated with a cost savings of approximately US$141 116 for both chemotherapy costs and hospital day avoidance. CONCLUSION: EPOCH-containing regimens can be safely administered in the outpatient setting, which may result in cost savings for healthcare institutions.
Assuntos
Assistência Ambulatorial/economia , Protocolos de Quimioterapia Combinada Antineoplásica/economia , Custos e Análise de Custo/normas , Hospitalização/economia , Linfoma não Hodgkin/tratamento farmacológico , Linfoma não Hodgkin/economia , Adulto , Idoso , Idoso de 80 Anos ou mais , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Ciclofosfamida/administração & dosagem , Ciclofosfamida/economia , Doxorrubicina/administração & dosagem , Doxorrubicina/economia , Esquema de Medicação , Etoposídeo/administração & dosagem , Etoposídeo/economia , Feminino , Humanos , Pacientes Internados , Masculino , Pessoa de Meia-Idade , Pacientes Ambulatoriais , Prednisona/administração & dosagem , Prednisona/economia , Estudos Prospectivos , Estudos Retrospectivos , Vincristina/administração & dosagem , Vincristina/economiaRESUMO
AIM: To describe drugs used in the non-hormonal treatment of metastatic prostate cancer. MATERIAL: Bibliographical search was performed from the database Medline (National Library of Medicine, PubMed) and websites of the HAS and the ANSM. The search was focused on the characteristics, the mode of action, the efficiency and the side effects of the various drugs concerned. RESULTS: The metabolic radiotherapy although under-used for this indication, kept a place at the beginning of the disease. Radium-223 chloride seems to have to occupy an important place in the coming years. The chemotherapy, the only recourse until very recently in the castration-resistant prostate cancer, must redefine its place partially. The denosumab provide an interesting alternative to bisphosphonates. CONCLUSION: The non-hormonal treatment of the metastatic disease of the prostate cancer is changing rapidly with the emergence of new molecules. Urologist must know perfectly these new drugs.
Assuntos
Antineoplásicos/uso terapêutico , Neoplasias da Próstata/terapia , Anticorpos Monoclonais Humanizados/uso terapêutico , Antineoplásicos/economia , Antineoplásicos/farmacologia , Conservadores da Densidade Óssea/uso terapêutico , Cisplatino/economia , Cisplatino/farmacologia , Cisplatino/uso terapêutico , Denosumab , Docetaxel , Etoposídeo/economia , Etoposídeo/farmacologia , Etoposídeo/uso terapêutico , Humanos , Masculino , Mitoxantrona/economia , Mitoxantrona/farmacologia , Mitoxantrona/uso terapêutico , Compostos Organometálicos/economia , Compostos Organometálicos/farmacologia , Compostos Organometálicos/uso terapêutico , Compostos Organofosforados/economia , Compostos Organofosforados/farmacologia , Compostos Organofosforados/uso terapêutico , Osteoporose/etiologia , Osteoporose/prevenção & controle , Neoplasias da Próstata/patologia , Ligante RANK/antagonistas & inibidores , Proteção Radiológica/métodos , Radioisótopos/economia , Radioisótopos/farmacologia , Radioisótopos/uso terapêutico , Rádio (Elemento)/economia , Rádio (Elemento)/farmacologia , Rádio (Elemento)/uso terapêutico , Estrôncio/economia , Estrôncio/farmacologia , Estrôncio/uso terapêutico , Radioisótopos de Estrôncio/economia , Radioisótopos de Estrôncio/farmacologia , Radioisótopos de Estrôncio/uso terapêutico , Taxoides/economia , Taxoides/farmacologia , Taxoides/uso terapêuticoRESUMO
AIM: To describe drugs used in the chemotherapy of testis and penis neoplasms. MATERIAL: Bibliographical search was performed from the database Medline (National Library of Medicine, PubMed) and websites of the HAS and the ANSM. The search was focused on the characteristics, the mode of action, the efficiency and the side effects of the various drugs concerned. RESULTS: Nowadays, the chemotherapy is perfectly codified in adjuvant treatment or in first-line treatment of metastatic testis cancer. A single dose of carboplatin for seminoma testicular (stage I) in adjuvant treatment situation is one of the latest advances. Concerning penis cancer, the optimal protocols validated by a high level of evidence are missing. CONCLUSION: The chemotherapy in testis and penis neoplasms knew few advances in recent years. So, it is necessary to include patients in clinical research protocols.
Assuntos
Neoplasias Penianas/tratamento farmacológico , Neoplasias Testiculares/tratamento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/economia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Bleomicina/economia , Bleomicina/uso terapêutico , Carboplatina/economia , Carboplatina/uso terapêutico , Quimioterapia Adjuvante , Cisplatino/economia , Cisplatino/uso terapêutico , Criopreservação , Etoposídeo/economia , Etoposídeo/uso terapêutico , Fluoruracila/economia , Fluoruracila/uso terapêutico , Humanos , Ifosfamida/economia , Ifosfamida/uso terapêutico , Masculino , Metotrexato/economia , Metotrexato/uso terapêutico , Terapia Neoadjuvante , Metástase Neoplásica , Neoplasias Embrionárias de Células Germinativas/terapia , Orquiectomia , Paclitaxel/economia , Paclitaxel/uso terapêutico , Espermatozoides , Vimblastina/economia , Vimblastina/uso terapêuticoRESUMO
The effectiveness of stem cell mobilization with G-CSF in lymphoma patients is suboptimal. We reviewed our institutional experience using chemomobilization with etoposide (VP-16; 375 mg/m(2) on days +1 and +2) and G-CSF (5 µg/kg twice daily from day +3 through the final day of collection) in 159 patients with lymphoma. This approach resulted in successful mobilization (>2 × 10(6) CD34+ cells collected) in 94% of patients (83% within 4 apheresis sessions). Fifty-seven percent of patients yielded at least 5 × 10(6) cells in îº2 days and were defined as good mobilizers. The regimen was safe with a low rate of rehospitalization. Average costs were $14 923 for good mobilizers and $27 044 for poor mobilizers (P<0.05). Using our data, we performed a 'break-even' analysis that demonstrated that adding two doses of Plerixafor to predicted poor mobilizers at the time of first CD34+ cell count would achieve cost neutrality if the frequency of good mobilizers were to increase by 21%, while the frequency of good mobilizers would need to increase by 25% if three doses of Plerixafor were used. We conclude that chemomobilization with etoposide and G-CSF in patients with lymphoma is effective, with future opportunities for cost-neutral improvement using novel agents.
Assuntos
Antineoplásicos Fitogênicos , Etoposídeo , Mobilização de Células-Tronco Hematopoéticas/economia , Transplante de Células-Tronco Hematopoéticas/economia , Doença de Hodgkin , Linfoma não Hodgkin , Adulto , Idoso , Fármacos Anti-HIV/administração & dosagem , Fármacos Anti-HIV/economia , Antineoplásicos Fitogênicos/administração & dosagem , Antineoplásicos Fitogênicos/economia , Autoenxertos , Benzilaminas , Custos e Análise de Custo , Ciclamos , Etoposídeo/administração & dosagem , Etoposídeo/economia , Feminino , Fator Estimulador de Colônias de Granulócitos/administração & dosagem , Fator Estimulador de Colônias de Granulócitos/economia , Mobilização de Células-Tronco Hematopoéticas/métodos , Transplante de Células-Tronco Hematopoéticas/métodos , Compostos Heterocíclicos/administração & dosagem , Compostos Heterocíclicos/economia , Doença de Hodgkin/economia , Doença de Hodgkin/terapia , Humanos , Linfoma não Hodgkin/economia , Linfoma não Hodgkin/terapia , Masculino , Pessoa de Meia-IdadeRESUMO
Ten percent to 20% of patients with Hodgkin Lymphoma (HL) are refractory to first-line therapy or relapse. Existing salvage regimens have response rates of 60-85%, considerable toxicity and frequent treatment delay or dose reduction. We report a gemcitabine, cisplatin, and dexamethasone regimen (GemCis) with intensive growth factor and platelet support and no treatment delay. Seventeen patients with relapsed or refractory biopsy proven HL were treated. Toxicity, transfusion requirement, stem cell harvesting and engraftment data were collected. Response assessment was by computed tomography and positron emission tomography. Overall and complete response rates were high (94% and 65%, respectively). There were no episodes of febrile neutropenia, treatment delays or hospital admissions. All 15 patients intended for autograft were successfully harvested. All engrafted successfully with a median time for the entire group to neutrophil engraftment of 14 days. With a median follow-up of 22 months, the median survival has not yet been reached, and the estimated 2-year survival is 88%. GemCis is a well-tolerated outpatient regimen for relapsed/ refractory Hodgkin lymphoma which does not inhibit stem cell mobilisation, gives excellent response rates and compares favourably with previously published salvage regimens using these or other chemotherapy agents.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Transplante de Células-Tronco Hematopoéticas , Doença de Hodgkin/tratamento farmacológico , Terapia de Salvação , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/economia , Transfusão de Sangue/economia , Cisplatino/administração & dosagem , Cisplatino/efeitos adversos , Cisplatino/economia , Terapia Combinada , Citarabina/economia , Desoxicitidina/administração & dosagem , Desoxicitidina/efeitos adversos , Desoxicitidina/análogos & derivados , Desoxicitidina/economia , Dexametasona/administração & dosagem , Dexametasona/efeitos adversos , Dexametasona/economia , Intervalo Livre de Doença , Esquema de Medicação , Avaliação de Medicamentos , Resistencia a Medicamentos Antineoplásicos , Etoposídeo/economia , Feminino , Seguimentos , Fatores de Crescimento de Células Hematopoéticas/uso terapêutico , Doença de Hodgkin/cirurgia , Humanos , Masculino , Metilprednisolona/economia , Pessoa de Meia-Idade , Neutropenia/induzido quimicamente , Neutropenia/epidemiologia , Neutropenia/prevenção & controle , Recidiva , Estudos Retrospectivos , Transplante Autólogo , Adulto Jovem , GencitabinaRESUMO
OBJECTIVES: With new oral chemotherapy drugs emerging, it is useful to understand the costs associated with traditional intravenous (IV) therapy. This study aims to assess costs associated with IV chemotherapy in patients with small cell lung cancer (SCLC) from the perspective of large employer-payers. STUDY DESIGN: Descriptive retrospective claims database analysis. METHODS: Using medical claims data from 5.5 million beneficiaries between 01/01/1998 and 01/31/2006, we identified patients with lung cancer (ICD-9 codes 162.3-162.9, 176.4, or 197.0) who received IV chemotherapy. A case-finding SCLC algorithm was then applied which selected patients who were treated with chemotherapies commonly used in SCLC (cisplatin/etoposide, cisplatin/irinotecan, carboplatin/etoposide, topotecan, or cyclophosphamide/doxorubicin/vincristine) and then excluded those who had treatments or procedures indicative of non-small cell lung cancer (NSCLC) (positron emission tomography [PET] scan imaging, lung surgery, common NSCLC chemotherapies). Average total costs paid per day of IV chemotherapy administration were computed, along with separate costs for IV chemotherapy drugs, IV chemotherapy administration procedures, and other drugs and services received on IV visit days. Costs were also estimated per course of treatment based on the assumption of four chemotherapy cycles per course with three visits per cycle. RESULTS: Among 8010 patients with a lung cancer diagnosis, 802 were identified as SCLC. In the SCLC subset, the average total daily cost was $787 ($9449/course), with $395 ($4742/course; 50.2%) attributable to IV chemotherapy drugs, $93 ($1112/course; 11.8%) to IV chemotherapy administration, and $300 ($3595/course; 38.0%) to other drugs and services. CONCLUSIONS: The proposed algorithm identified about 10% of patients with lung cancer receiving IV chemotherapy as likely SCLC cases. Future studies should validate this algorithm with medical records data. IV chemotherapy administration and other visit-related drugs and services represented about half of the total cost per IV visit day, with the remainder attributable to direct costs for IV chemotherapy drugs.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/economia , Carcinoma de Células Pequenas/economia , Administração Oral , Idoso , Algoritmos , Camptotecina/administração & dosagem , Camptotecina/análogos & derivados , Camptotecina/economia , Carboplatina/administração & dosagem , Carboplatina/economia , Carcinoma de Células Pequenas/tratamento farmacológico , Cisplatino/administração & dosagem , Cisplatino/economia , Análise Custo-Benefício , Ciclofosfamida/administração & dosagem , Ciclofosfamida/economia , Doxorrubicina/administração & dosagem , Doxorrubicina/economia , Etoposídeo/administração & dosagem , Etoposídeo/economia , Feminino , Custos de Cuidados de Saúde , Humanos , Infusões Intravenosas/economia , Revisão da Utilização de Seguros , Irinotecano , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Topotecan/administração & dosagem , Topotecan/economia , Estados Unidos , Vincristina/administração & dosagem , Vincristina/economiaRESUMO
BACKGROUND: In patients with small-volume disseminated disease of germ cell tumors, cure can be achieved with four cycles of bleomycin, etoposide, and cisplatin (BEP). However, around 20% of these cases are not curable. Strategies to improve cure rates have shown that none of the currently available modalities were superior to the others. Among the most used ones, BEP and VIP (etoposide, cisplatin, and ifosfamide) have been the most studied. However, there are no reports comparing the two, except for a few in abstract forms from southern India. Therefore, we did a treatment outcome and cost-effectiveness analysis of two chemotherapeutic regimens (BEP vs VIP) that are used in poor-prognosis metastatic germ cell tumors. MATERIALS AND METHODS: All male patients with germ cell tumors, diagnosed as having poor risk by IGCCCG, between January 2002 and December 2004 were included in the study. Clinical, laboratory, and other data were recorded. The patients were stratified into two categories on the basis of the type of chemotherapeutic regimen they received. RESULTS: In all, 46 patients were analyzed, with a median follow up of 26.6 months. The baseline characteristics (age, stage, PS, histology, and serum markers) were not different in the two treatment arms. There is no significant difference in the outcome with either of the chemotherapeutic modalities. VIP is less cost effective and more toxic compared to BEP. CONCLUSION: In view of the greater toxicity and cost of therapy, as well as lack of either overall or disease free survival advantage, VIP is not a preferred option for patients with high-risk germ cell tumors in the Indian setting and it is still advisable to treat patients with BEP.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/economia , Neoplasias Embrionárias de Células Germinativas/tratamento farmacológico , Neoplasias Embrionárias de Células Germinativas/patologia , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Bleomicina/efeitos adversos , Bleomicina/economia , Bleomicina/uso terapêutico , Cisplatino/efeitos adversos , Cisplatino/economia , Cisplatino/uso terapêutico , Análise Custo-Benefício , Etoposídeo/efeitos adversos , Etoposídeo/economia , Etoposídeo/uso terapêutico , Humanos , Ifosfamida/efeitos adversos , Ifosfamida/economia , Ifosfamida/uso terapêutico , Masculino , Pessoa de Meia-Idade , Metástase Neoplásica , Podofilotoxina/efeitos adversos , Podofilotoxina/economia , Podofilotoxina/uso terapêutico , Prognóstico , Resultado do TratamentoRESUMO
BACKGROUND: The use of granulocyte colony-stimulating factor (G-CSF) can enable dose intensification of chemotherapy in small-cell lung cancer (SCLC). However, given its acquisition cost, it is important to assess its cost effectiveness within a resource-constrained health service. OBJECTIVE: To assess the cost effectiveness, from the UK NHS perspective, of G-CSF given in addition to doxorubicin, cyclophosphamide and etoposide (ACE) versus ACE alone in the management of SCLC. METHODS: Using data from a UK Medical Research Council trial (LU19) to assess chemotherapy dose intensification in patients with previously untreated SCLC of any disease extent, a retrospective cost-effectiveness analysis was undertaken. Resource use data, including hospitalisations and non-protocol cancer treatments, were collected during the first 6-month treatment phase of the trial. Mean costs ( pound, 2003 values) of managing patients in the two arms of the trial were calculated. Mean survival duration was calculated for the two groups using patient-specific follow-up data collected in the trial. Incremental cost-effectiveness analysis was undertaken, and uncertainty in cost effectiveness was expressed using cost-effectiveness acceptability curves. RESULTS: The use of G-CSF in addition to ACE chemotherapy is more costly ( 4647 pounds) but results in longer mean survival duration (0.20 years; 0.18 years when discounted). This generates an incremental cost per additional life-year of 25,816 pounds for ACE + G-CSF therapy. The probability of the addition of G-CSF being cost effective, if decision makers are willing to pay 30,000 pounds for an additional life-year, is 0.57. Secondary analysis suggests that cost effectiveness is likely to be sensitive to assumptions about the health-related quality of life (HR-QOL) experienced by patients. CONCLUSION: Based on data collected in the LU19 trial, chemotherapy dose intensification using G-CSF in SCLC adds to health service costs but increases survival duration. Its overall cost effectiveness is likely to be finely balanced.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma de Células Pequenas/tratamento farmacológico , Fator Estimulador de Colônias de Granulócitos/administração & dosagem , Neoplasias Pulmonares/tratamento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/economia , Carcinoma de Células Pequenas/economia , Carcinoma de Células Pequenas/mortalidade , Análise Custo-Benefício , Ciclofosfamida/administração & dosagem , Ciclofosfamida/economia , Relação Dose-Resposta a Droga , Doxorrubicina/administração & dosagem , Doxorrubicina/economia , Etoposídeo/administração & dosagem , Etoposídeo/economia , Fator Estimulador de Colônias de Granulócitos/economia , Fator Estimulador de Colônias de Granulócitos/farmacologia , Humanos , Neoplasias Pulmonares/economia , Neoplasias Pulmonares/mortalidade , Pessoa de Meia-Idade , Anos de Vida Ajustados por Qualidade de Vida , Ensaios Clínicos Controlados Aleatórios como Assunto , Estudos Retrospectivos , Medicina Estatal/economia , Análise de SobrevidaRESUMO
The development of alternatives to hospitalisation is mandatory in cancer patients. A retrospective analysis compared the costs relative to two modalities of administration of VAD chemotherapy (hospital versus outpatient) in multiple myeloma. This study was carried out from the perspective of the French health care system, including direct hospital and ambulatory costs. The robustness of results was tested in a sensitivity analysis. Forty four patients were included: 27 in the "hospitalisation" arm and 17 in the "outpatient" arm. Among the cycles planned to be administered in outpatient, only 5 cycles (4 patients) have to be administered in hospital. The length of hospitalisation was consequently reduced with outpatient administration (-11.2 days) and it induced a significant cost saving as 3,066 euros (-32%) per patient. In sensitivity analysis, this cost saving varied from 1,282 to 3,667 euros. Our study showed the safety and the economic interest of outpatient administration of VAD chemotherapy in multiple myeloma. Facilities and training are required to develop ambulatory chemotherapy.
Assuntos
Assistência Ambulatorial/economia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Hospitalização/economia , Mieloma Múltiplo/tratamento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/economia , Doxorrubicina/economia , Doxorrubicina/uso terapêutico , Etoposídeo/economia , Etoposídeo/uso terapêutico , Feminino , França , Custos Hospitalares , Humanos , Masculino , Pessoa de Meia-Idade , Mieloma Múltiplo/economia , Estudos Retrospectivos , Sensibilidade e EspecificidadeRESUMO
High-dose epirubicin plus cisplatin was compared with the reference regimen of etoposide/cisplatin in small-cell lung cancer (SCLC). Four hundred two previously untreated patients with SCLC were randomized to receive etoposide 100 mg/m(2) on days 1-3 and cisplatin 100 mg/m(2) on day 1 or epirubicin 100 mg/m(2) and cisplatin 100 mg/m(2) on day 1 every 21 days for a total of 6 cycles. Patients were stratified according to treatment center and extent of disease (limited disease, n = 207; extensive disease, n = 195). Patients with limited disease were treated with thoracic radiation therapy after completion of chemotherapy, and those who exhibited a complete response were advised to receive prophylactic cranial irradiation. The primary endpoint was survival, and secondary endpoints were time to progression (TTP), response, toxicity, and costs. Patient characteristics were generally well balanced in the 2 arms, even though more patients in the epirubicin/cisplatin arm had > 5% weight loss and poor Karnofsky performance index compared with the etoposide/cisplatin arm. One hundred thirty-four patients (66.3%) in the etoposide/cisplatin arm and 126 (63.0%) in the epirubicin/cisplatin arm received all 6 planned cycles of chemotherapy. Response rate, TTP, and survival did not differ significantly between the 2 arms. Grade 3/4 neutropenia and toxic deaths occurred more frequently in the etoposide/cisplatin arm. Epirubicin/cisplatin showed a similar activity with a slightly lower toxicity profile than the reference regimen of etoposide/cisplatin. The epirubicin/cisplatin regimen may be recommended in the treatment of SCLC.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma de Células Pequenas/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Adulto , Idoso , Antibacterianos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/economia , Carcinoma de Células Pequenas/mortalidade , Carcinoma de Células Pequenas/radioterapia , Cisplatino/administração & dosagem , Cisplatino/efeitos adversos , Cisplatino/economia , Irradiação Craniana , Relação Dose-Resposta a Droga , Esquema de Medicação , Epirubicina/administração & dosagem , Epirubicina/efeitos adversos , Epirubicina/economia , Transfusão de Eritrócitos/estatística & dados numéricos , Etoposídeo/administração & dosagem , Etoposídeo/efeitos adversos , Etoposídeo/economia , Feminino , Hospitalização/estatística & dados numéricos , Humanos , Neoplasias Pulmonares/mortalidade , Neoplasias Pulmonares/radioterapia , Masculino , Pessoa de Meia-Idade , Transfusão de Plaquetas/estatística & dados numéricos , Estudos Prospectivos , Radioterapia AdjuvanteAssuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma de Células Pequenas/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/economia , Carcinoma de Células Pequenas/mortalidade , Esquema de Medicação , Custos de Medicamentos , Etoposídeo/administração & dosagem , Etoposídeo/economia , Feminino , Seguimentos , Humanos , Ifosfamida/administração & dosagem , Ifosfamida/economia , Índia , Neoplasias Pulmonares/mortalidade , Masculino , Mesna/administração & dosagem , Mesna/economia , Pessoa de Meia-Idade , Cooperação do Paciente , Pobreza , Análise de Sobrevida , Taxa de Sobrevida , Resultado do Tratamento , Vincristina/administração & dosagem , Vincristina/economiaRESUMO
To compare etoposide and etoposide phosphate (Etopophos; Bristol-Myers Squibb Company, Princeton, NJ) in maximizing the cost efficiency of care for patients with small cell lung cancer (SCLC), we obtained pharmacoeconomic data from a phase II randomized study of these agents. This clinical investigation assessed the efficacy and toxicity of etoposide phosphate combined with cisplatin in treating SCLC. In the economic analysis, we identified resources expended during chemotherapy and related concomitant procedures and matched them with the current procedure terminology level of costs for the provider and the payor. The valuation process was conducted in the specific point-of-care (outpatient v inpatient) setting. The appropriate pharmacoeconomic analytic tool used when comparators are considered to achieve equivalent clinical outcomes is cost-minimization analysis. We provide the cost-minimization analysis from two oncology care perspectives: the provider and the payor. In addition, a payor/ provider cost reduction model was constructed to illustrate the potential economic effects achieved through more efficient use of the outpatient chemotherapy facility due to the ease of administration of etoposide phosphate. The provider's average cost per patient for treating an SCLC patient for six cycles in US dollars is $26,764.48 for etoposide versus $26,026.70 for etoposide phosphate. The payor's average treatment cost per patient for treating an SCLC patient for six cycles for the respective regimens was $34,270.65 and $34,320.70. When the time savings associated with the etoposide phosphate regimen are applied to the outpatient chemotherapy facility, the adjusted average treatment costs per patient for the payor are $2,797.29 less than the costs for using the standard etoposide intravenous formulation. Delivering an etoposide phosphate regimen accrued adjusted savings of $2,897.03 per patient. Based on these results, etoposide phosphate is a superior pharmacoeconomic alternative compared with standard etoposide chemotherapy in managing SCLC. The potential increase in patient volume conferred by the relative simplicity of etoposide phosphate administration would have a significant impact on operations in terms of scheduling patients and staff and increasing operational efficiencies, thereby facilitating cost reductions in excess of $2,700 per patient when an etoposide phosphate regimen is chosen over an etoposide regimen.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/economia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma de Células Pequenas/tratamento farmacológico , Etoposídeo/análogos & derivados , Etoposídeo/economia , Neoplasias Pulmonares/tratamento farmacológico , Compostos Organofosforados/economia , Carcinoma de Células Pequenas/economia , Cisplatino/administração & dosagem , Cisplatino/economia , Custos e Análise de Custo , Farmacoeconomia , Etoposídeo/administração & dosagem , Humanos , Neoplasias Pulmonares/economia , Modelos Econômicos , Compostos Organofosforados/administração & dosagemRESUMO
The cost-effectiveness of four cisplatin-containing chemotherapy regimens used in the treatment of non-small cell lung cancer (NSCLC) stages III B and IV was retrospectively assessed specifically with respect to the situation in Italy and from the third party payer perspective. The chemotherapy regimens compared were gemcitabine+cisplatin (G + C), mitomycin+ifosfamide+cisplatin (MIP), etoposide+cisplatin (E + C), and vinorelbine+cisplatin (V + C). Efficacy and safety data for the regimens were calculated from studies selected from the international literature using formal inclusion and exclusion criteria. In total, one study with one G + C treatment arm (48 patients), one study with one MIP treatment arm (133 patients), three studies with one E + C treatment arm (total 325 patients), and two studies with one V + C treatment arm (total 327 patients) were included. Where efficacy and toxicity results for the same regimen were reported in more than one study, the values were combined using a random effects meta-analysis method. The mean tumour response rates were: 54% (95% confidence intervals (CI) 40-69%); 40% (95% CI 32-49%); 26% (95% CI 20-30%); and 35% (95% CI 24-48) for G + C, MIP, E + C and V + C, respectively. Costs were evaluated for World Health Organization (WHO) grade 3 and 4 toxicities with high impact on medical costs using computer modelling techniques. The official prices of drugs and official reimbursement rates were used to calculate direct medical costs. Average cost-effectiveness analysis demonstrated no significant difference between the treatments. Marginal cost-effectiveness analysis showed that the use of MIP, E + C or V + C instead of G + C would result in additional costs of 7.7, 55.2 (p < 0.05), and 46.2 million lira, respectively, for every patient with a tumour response.